JP Patent

JP6930060B2 — 新規なジヒドロピラノピリミジノン誘導体およびその用途｛Ｎｏｖｅｌ ｄｉｈｙｄｒｏｐｙｒａｎｏｐｙｒｉｍｉｄｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ、ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝

Assigned to エスティ ファーム カンパニー リミテッド · Expires 2021-09-01 · 5y expired

What this patent protects

Patent listed against Romvimza.

Drugs covered by this patent

Patent Metadata

Patent number
JP6930060B2
Jurisdiction
JP
Classification
—
Expires
2021-09-01
Drug substance claim
No
Drug product claim
No
Assignee
エスティ ファーム カンパニー リミテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.